MedAdvisor Limited (AU:AHE)
ASX:AHE
Want to see AU:AHE full AI Analyst Report?
AHE Stock Chart & Stats
AU$0.02
>-AU$0.01(-5.56%)
―
--
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.09
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.73M
Market Cap
AU$10.84M
Enterprise ValueAU$17.93M
Total Cash (Recent Filing)AU$10.30M
Total Debt (Recent Filing)AU$17.40M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding637,676,800
10 Day Avg. Volume474,818
30 Day Avg. Volume1,728,714
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)11.59
Price to Sales (P/S)0.19
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$110.67M
Bulls Say, Bears Say
Bulls Say
Improving Free Cash Flow GrowthAn 18.49% increase in free cash flow points to improving cash conversion even while earnings are negative. Sustained FCF growth can extend operational runway, fund product development or restructuring, and reduce near-term external financing needs over the next several quarters.
Pharmacy-focused Platform With Consumer AppThe combined pharmacy software and consumer app creates a two-sided network connecting pharmacies and patients, increasing stickiness of refill and adherence workflows. This structural positioning supports recurring revenue streams and partnership monetisation opportunities over the medium term.
Positive Return On EquityA positive ROE amid a weak balance sheet suggests the business can generate returns from invested capital when scaled. If management stabilises the balance sheet, this operational efficiency could translate to faster recovery in profitability and improved capital allocation over time.
Bears Say
Sharp Revenue DeclineA nearly 40% revenue contraction materially reduces scale economics and weakens pricing and partnership leverage. Lower top-line volume makes fixed-cost absorption harder, pressures margin recovery, and lengthens the timeline needed for sustainable profitability absent a clear revenue turnaround.
Deep Negative MarginsVery large negative margins indicate the core business currently loses substantial cash on operations. This unsustainable cost structure requires either meaningful revenue growth, significant cost trimming, or fresh capital to avoid continued erosion of liquidity and to enable long-term investment.
Precarious Balance Sheet And Negative EquityNegative shareholders' equity and a distorted debt-to-equity metric signal solvency concerns and limited financial flexibility. This condition constrains borrowing capacity, raises refinancing risk, and heightens vulnerability to shocks, complicating recovery and strategic initiatives over the medium term.
MedAdvisor Limited News
AHE FAQ
What was MedAdvisor Limited’s price range in the past 12 months?
MedAdvisor Limited lowest share price was AU$0.02 and its highest was AU$0.09 in the past 12 months.
What is MedAdvisor Limited’s market cap?
MedAdvisor Limited’s market cap is AU$10.84M.
When is MedAdvisor Limited’s upcoming earnings report date?
MedAdvisor Limited’s upcoming earnings report date is Aug 27, 2026 which is in 66 days.
How were MedAdvisor Limited’s earnings last quarter?
MedAdvisor Limited released its earnings results on Feb 26, 2026. The company reported AU$0.011 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.011.
Is MedAdvisor Limited overvalued?
According to Wall Street analysts MedAdvisor Limited’s price is currently Undervalued.
Does MedAdvisor Limited pay dividends?
MedAdvisor Limited does not currently pay dividends.
What is MedAdvisor Limited’s EPS estimate?
MedAdvisor Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MedAdvisor Limited have?
MedAdvisor Limited has 637,676,800 shares outstanding.
What happened to MedAdvisor Limited’s price movement after its last earnings report?
MedAdvisor Limited reported an EPS of AU$0.011 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MedAdvisor Limited?
Currently, no hedge funds are holding shares in AU:AHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MedAdvisor Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:AHE Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$20.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.95%
12-Months-Change
Fundamentals
Return on Equity
-209.68%
Trailing 12-Months
Asset Growth
-72.24%
Trailing 12-Months
Company Description
MedAdvisor Limited
Adheris Health Limited, through its affiliates, specializes in delivering pharmacy-led patient interaction platforms. It serves markets in Australia, the United States, and the United Kingdom. The company's flagship product is THRiV, an integrated omni-channel system. THRiV aims to optimize medication adherence and administration by empowering pharmacies to foster engagement with both patients and fellow pharmacists. Formerly operating as MedAdvisor Limited, the company adopted the Adheris Health Limited designation in November 2025. Established in 2010, its corporate base is situated in Woburn, Massachusetts.
Options Prices
Currently, No data available
---